Precision Medicine

PET-PSMA: The Future of Diagnosis in Urology

Dr. Bruno Benigno | CRM-SP 126265
Specialist in Urologic Oncology and Robotic Surgery. Early detection and personalized treatment for prostate cancer.

See Explanation Book your consultation now

Lattes

Dr. Bruno Benigno

Certified Robotic Surgeon
Full Member of the SBU
Hospital Sírio-Libanês & BP

Hospital Sírio-Libanês • Hospital Alemão Oswaldo Cruz • BP - A Beneficência Portuguesa • Sociedade Brasileira de Urologia (Brazilian Society of Urology)

Understanding PET-PSMA Technology

Watch the explanatory video on how molecular mapping is revolutionizing prostate cancer treatment.

Focus on Urologic Oncology

Prostate Cancer

A comprehensive approach, from molecular diagnosis (PET-PSMA) to high-precision Robotic Surgery.

Reference

Robotic Surgery

Minimally invasive procedures with faster recovery and preservation of vital functions.

Da Vinci Technology

Kidney and Bladder Cancer

Advanced treatments for complex tumors, using organ-sparing techniques.

Complexity

Career and Excellence

2005 - 2011

Education and Specialization

Medical degree and residency in Urology at the Federal University of São Paulo (UNIFESP).

2012 - 2018

International Training

Intensive training in Robotic Surgery and Fellowship in Urologic Oncology at Hospital Sírio-Libanês.

Today

Leadership in Urologic Oncology

Team coordinator, international speaker and specialist in complex urological cancer cases.

Our Facilities

Technology and comfort for the best care.

What patients say

“An excellent professional. Very attentive, and he explains everything clearly. He made me feel very confident about the robotic procedure.”

R.S. (São Paulo)

Review via Doctoralia

“Dr. Bruno is a reference in his field. Compassionate care and a top-notch support team. I highly recommend him.”

M.F. (Campinas)

Review via Doctoralia

“I had my staging done with PET-PSMA following his advice, and it completely changed the treatment strategy for the better.”

A.G. (Alphaville)

Review via Doctoralia

See all reviews on Doctoralia

Frequently Asked Questions

PET-PSMA is a highly sensitive molecular imaging test that uses a tracer specific to prostate cancer cells. It can detect sites of disease at very early stages, or recurrences, that other common tests might miss.

Institutional Affiliations

Hospital Sírio-Libanês A Beneficência Portuguesa (BP) Hospital Alemão Oswaldo Cruz Sociedade Brasileira de Urologia (SBU)

Cutting-Edge Treatment, Human Care

We are ready to offer the most accurate diagnosis and the best treatment strategy for your case.

WhatsApp Phone YouTube Book

Rua Borges Lagoa, 1070, Conjunto 131, Cobertura — Vila Clementino, São Paulo/SP, CEP 04038-002

Scientific references

The information on this page is based on the guidelines and studies below, published in peer-reviewed medical journals.

Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. PubMed · DOI 10.1016/S0140-6736(20)30314-7

proPSMA randomized trial: in the staging of high-risk prostate cancer, PSMA PET was more accurate than CT combined with bone scan.

Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856-863. PubMed · DOI 10.1001/jamaoncol.2019.0096

Prospective study: 68Ga-PSMA-11 PET localized biochemical recurrence of prostate cancer with high accuracy.

Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-417. PubMed · DOI 10.1016/j.eururo.2019.01.049

Systematic review and meta-analysis: the detection rate of PSMA PET increases with the PSA level at biochemical recurrence.

Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466-1486. PubMed · DOI 10.1007/s00259-022-06089-w

Joint EANM/SNMMI guideline standardizing the indications, performance and interpretation of PSMA PET.

Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-182. PubMed · DOI 10.1016/j.eururo.2024.04.010

European (EAU) 2024 guideline on relapsing and metastatic prostate cancer, including the use of PSMA PET in biochemical recurrence.